317 related articles for article (PubMed ID: 29464437)
1. Cutaneous Manifestations of Reactions to Biologics.
Otani IM; Levin AS; Banerji A
Curr Allergy Asthma Rep; 2018 Feb; 18(2):12. PubMed ID: 29464437
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects of biologic drugs in psoriasis: a literature review.
Šuler Baglama Š; Trčko K
Acta Dermatovenerol Alp Pannonica Adriat; 2021 Dec; 30(4):149-156. PubMed ID: 34929991
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.
Garcovich S; De Simone C; Genovese G; Berti E; Cugno M; Marzano AV
Front Pharmacol; 2019; 10():282. PubMed ID: 30971924
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective.
Succaria F; Bhawan J
J Dermatol; 2017 Mar; 44(3):243-250. PubMed ID: 28256759
[TBL] [Abstract][Full Text] [Related]
5. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.
Carrascosa JM; Del-Alcazar E
Expert Rev Clin Immunol; 2018 Apr; 14(4):259-273. PubMed ID: 29557200
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity and Immune-related Adverse Events in Biologic Therapy.
Waldron JL; Schworer SA; Kwan M
Clin Rev Allergy Immunol; 2022 Jun; 62(3):413-431. PubMed ID: 34319562
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic.
Balakirski G; Merk HF
Cutan Ocul Toxicol; 2017 Dec; 36(4):307-316. PubMed ID: 28412864
[TBL] [Abstract][Full Text] [Related]
8. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
9. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
Rongioletti F; Burlando M; Parodi A
G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity reactions during treatment with biological agents.
Puxeddu I; Caltran E; Rocchi V; Del Corso I; Tavoni A; Migliorini P
Clin Exp Rheumatol; 2016; 34(1):129-32. PubMed ID: 26751942
[TBL] [Abstract][Full Text] [Related]
12. Biologic treatment of psoriasis in oncologic patients.
Rusiñol L; Camiña-Conforto G; Puig L
Expert Opin Biol Ther; 2022 Dec; 22(12):1567-1578. PubMed ID: 36422998
[TBL] [Abstract][Full Text] [Related]
13. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
[TBL] [Abstract][Full Text] [Related]
14. Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases.
Dodson J; Lio PA
Curr Allergy Asthma Rep; 2022 Dec; 22(12):183-193. PubMed ID: 36348149
[TBL] [Abstract][Full Text] [Related]
15. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
16. Iatrogenic CNS demyelination in the era of modern biologics.
Kumar N; Abboud H
Mult Scler; 2019 Jul; 25(8):1079-1085. PubMed ID: 30767720
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of adverse drug reactions to biologics.
Clarke JB
Handb Exp Pharmacol; 2010; (196):453-74. PubMed ID: 20020272
[TBL] [Abstract][Full Text] [Related]
18. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis reactivation risk in dermatology.
Pescitelli L; Ricceri F; Prignano F
J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist.
Khan DA
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):115-20. PubMed ID: 27499538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
